Gender equity in pharma - celebrating historic women in pharma
As we continue to celebrate the contributions of women in the pharmaceutical field following International Day of Women and Girls in Science and in the lead up to International Women’s Day on March 8, 2023, we take a look at some of the historic pharmaceutical innovations and leadership milestones from women.
American biochemist and pharmacologist Gertrude Elion joined Burroughs–Wellcome (now GSK) in 1944 working in cancer research. During her tenure, she and her team developed the anti-cancer drugs tioguanine and mercaptopurine for the treatment of acute myeloid leukemia, acute lymphocytic leukemia, and acute promyelocytic leukemia, amongst others [i]. In 1978, Elion developed a class of antiviral drugs that more accurately killed a virus without harming health cells. She received the 1988 Nobel Prize in Physiology or Medicine with George H. Hitchins and Sir James Black for innovative drug development techniques known as rational drug design in which biochemical and metabolic differences between human cells and pathogens are targeted [ii].
Frances Oldham Kelsey took a solid stance against rising pressure from pharmaceutical manufacturers in the 60s when thalidomide was reported to cause birth defects in the children of women who ahd taken the drug in Europe. On top of a lack of clinical evidence to support the drug’s safety claims, Kelsey withheld approval in a move that would ultimately prevent further physical deformities in infants. Her resolution to remain firm shaped the FDA’s regulatory procedures, and she was appointed Deputy for scientific and medical affairs for the FDA’s CDER in 1995 [ii].
CEO of GSK Emma Walmsley is the first female CEO of a top 10 pharmaceutical company, where she has replaced 50 of GSK’s top 125 managers in a bid to increase diversity across the board since 2017 [iii]. With business and management experience in the pharmaceutical and consumer products industries, Emma is also a member of the GSK Leadership Team and President and CEO of GSK Consumer Healthcare [i]. In 2020 she was appointed Dame Commander of the British Empire for services to the pharmaceutical industry and business.
Heather Bresch similarly has held the rank of CEO of Mylan since 2021, becoming the first woman to lead a Fortune 500 pharmaceutical company. Various pharmaceutical pricing controversies have plagued the company, such as in 2016 when the EpiPen saw a 400% price hike. While Bresch stated the new pen design was superior, she pushed for the company to introduce another generic pen for half the price. She has also been a trailblazer in lobbying for increased transparency with regards to pharmaceutical pricing. In 2011, she was recognised by Esquire for her role in pushing forward the FDA’s Safety and Innovation Act [i].
[i] Trailblazing Women in Pharma History | Pharma Manufacturing
[ii] Women in the Pharmaceutical Sciences: Honoring Our Pioneers | SpringerLink
[iii] Glaxo CEO Replaced 50 Top Managers in Shakeup to Spur Growth - Bloomberg
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi. -
News Racial disparities in diagnosis and drug use for dementia symptoms
A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms. -
News MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb... -
News Drug Patent Expiries: a steep cliff or opportunity for innovation?
The pharmaceutical industry faces a patent cliff together in the years leading up to 2030. Learn what this means for drug pricing, their outsourcing partners, and drug innovation of the future.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance